April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
45 citations
,
January 2008 in “Drugs” Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
27 citations
,
May 2015 in “Neuropharmacology” Dutasteride protects dopamine neurons in Parkinson's mice, but Finasteride doesn't.
November 2005 in “PubMed”
7 citations
,
January 2018 in “Reproduction” Inhibiting 5α-reductase increases progesterone levels in late pregnant mares.
April 2011 in “Annals of Internal Medicine” Rivaroxaban and fondaparinux are effective for certain blood conditions, and hydroxyurea helps in sickle cell disease.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
6 citations
,
April 2022 in “Biomedicine & pharmacotherapy” Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
4 citations
,
October 2023 in “Journal of Medicine and Life” UDCA reduces inflammation and joint damage in rheumatoid arthritis.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
2 citations
,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
September 2025 in “Reactions Weekly” May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
21 citations
,
July 2014 in “Antimicrobial Agents and Chemotherapy” Finasteride effectively prevents biofilm formation and treats preformed biofilms, but requires high doses.
40 citations
,
January 2017 in “Intestinal Research” Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
June 2019 in “Reactions Weekly” 48 citations
,
February 2006 in “Molecular and Cellular Endocrinology” 5α-reductase inhibitors may reduce male fertility and could be used for male contraception.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
March 2023 in “Brazilian Journal of Health Review” The combination tablet of finasteride and doxazosin works the same as taking each drug separately.
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
A medicine company has recalled a drug because it contained an unlisted blood pressure medication.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
January 2020 in “International Journal of Research in Pharmacy and Chemistry” A reliable method was created to measure dutasteride and related molecules in capsules.
4 citations
,
October 2020 in “Research Square (Research Square)” Hydroxychloroquine, nitazoxanide, and ivermectin were similarly effective in treating early COVID-19.
7 citations
,
April 2007 in “PubMed” Finasteride, a hair loss drug, caused a skin rash that went away when the drug was stopped and returned when used again.